Beacon Investment Advisory Services Inc. purchased a new position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 4,043 shares of the company’s stock, valued at approximately $767,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AZN. Professional Advisory Services Inc. purchased a new stake in shares of Astrazeneca in the second quarter valued at about $30,241,000. Pursuit Wealth Management LLC purchased a new position in Astrazeneca during the fourth quarter worth about $636,000. Penobscot Investment Management Company Inc. lifted its position in Astrazeneca by 17.2% in the fourth quarter. Penobscot Investment Management Company Inc. now owns 83,539 shares of the company’s stock valued at $7,680,000 after purchasing an additional 12,255 shares during the period. Assetmark Inc. lifted its position in Astrazeneca by 8.1% in the fourth quarter. Assetmark Inc. now owns 335,387 shares of the company’s stock valued at $30,832,000 after purchasing an additional 25,004 shares during the period. Finally, Cambiar Investors LLC boosted its holdings in Astrazeneca by 2.0% in the 4th quarter. Cambiar Investors LLC now owns 276,150 shares of the company’s stock valued at $25,386,000 after purchasing an additional 5,326 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on AZN shares. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings lowered Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $211.00.
Astrazeneca Price Performance
AZN stock opened at $161.28 on Friday. The firm has a 50 day moving average of $176.34 and a 200-day moving average of $187.12. Astrazeneca Plc has a 12-month low of $145.79 and a 12-month high of $212.71. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47. The company has a market cap of $250.12 billion, a price-to-earnings ratio of 24.11, a PEG ratio of 1.39 and a beta of 0.26.
Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The business had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. During the same quarter in the prior year, the firm posted $2.17 EPS. The company’s revenue was up 6.4% compared to the same quarter last year. As a group, equities analysts expect that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Read More
- Five stocks we like better than Astrazeneca
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
